Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 101, Daehak-ro, Jongno-gu, Seoul, 03080, South Korea.
Department of Statistics and Actuarial Science, Soongsil University, Seoul, South Korea.
Sci Rep. 2024 Apr 2;14(1):7805. doi: 10.1038/s41598-024-58417-9.
Given the pleiotropic effects of statins beyond their lipid-lowering effects, there have been attempts to evaluate the role of statin therapy in IPF, but they have shown inconclusive results. Data from the National Health Insurance Service (NHIS) database of South Korea were used to investigate the effects of statin therapy on IPF. The IPF cohort consisted of a total of 10,568 patients who were newly diagnosed with IPF between 2010 and 2017. These patients were then matched in a 1:3 ratio to 31,704 subjects from a control cohort without IPF, with matching based on age and sex. A case-control study was performed to evaluate the association between statin use and the risk for IPF, and the multivariable analysis revealed that statin use was associated with a lower risk for IPF (adjusted OR 0.847, 95% CI 0.800-0.898). Using the IPF cohort, we also evaluated whether statin use at the time of diagnosis was associated with future clinical outcomes. The statin use at the time of IPF diagnosis was associated with improved overall survival (adjusted HR 0.779, 95% CI 0.709-0.856). Further prospective studies are needed to clarify the role of statin therapy in IPF.
鉴于他汀类药物除了降低血脂外还有多种作用，人们曾尝试评估他汀类药物治疗特发性肺纤维化（IPF）的作用，但结果尚无定论。本研究利用韩国国家健康保险服务（NHIS）数据库的数据，调查了他汀类药物治疗对 IPF 的影响。
IPF 队列包括总共 10568 名于 2010 年至 2017 年间被新诊断为 IPF 的患者。然后按照年龄和性别以 1:3 的比例与 31704 名无 IPF 的对照组患者进行匹配。采用病例对照研究评估他汀类药物使用与 IPF 风险之间的关系，多变量分析显示，他汀类药物使用与 IPF 风险降低相关（调整后的 OR 0.847，95%CI 0.800-0.898）。
在 IPF 队列中，我们还评估了 IPF 诊断时使用他汀类药物是否与未来的临床结局相关。IPF 诊断时使用他汀类药物与总体生存率的提高相关（调整后的 HR 0.779，95%CI 0.709-0.856）。需要进一步的前瞻性研究来阐明他汀类药物治疗在 IPF 中的作用。
